Updates From ACC

CVD, HF, and T2D

Antihyperglycemic Medications and CV Outcomes From RCTs Pre-2015

Antihyperglycemic Medications and Impact on HF From RCTs Pre-2015

EMPA-REG OUTCOME: Empagliflozin Primary MACE Outcome

EMPA-REG OUTCOME: Empagliflozin Attribution to MACE Reduction

EMPA-REG OUTCOME: Empagliflozin Hospitalization for HF

LEADER: Liraglutide Attribution to MACE Reduction

LEADER: Liraglutide Primary MACE Outcome

EMPA-REG OUTCOME vs LEADER

SUSTAIN-6: Semaglutide* Primary MACE Outcome

SUSTAIN-6: Semaglutide* Attribution to MACE Reduction

HF Benefit With Empagliflozin in Patients With and Without Established HF

HF Analyses LEADER and SUSTAIN-6

HF Analyses ELIXA -- Lixisenatide

FIGHT and LIVE Studies Liraglutide

CVD-REAL Study Questions Posed

CVD-REAL Study Patient Population

CVD-REAL Study Baseline Characteristics

CVD-REAL Study Contribution of SGLT2 Inhibitors

CVD-REAL Study HHF Primary Analysis

CVD-REAL Study All-Cause Death

CVD-REAL Study Limitations

Interpreting Real-World Data vs RCTs

CVD-REAL Study vs EMPA-REG OUTCOME

What to Look Forward to

Concluding Remarks

Abbreviations

Abbreviations (cont)